- Research Article
- 10.25258/ijcpr.18.3.45
Evaluation of Serum Inflammatory Biomarkers and Disease Severity Correlation in Patients with Chronic Plaque Psoriasis: A Cross-Sectional Study
- Mar 11, 2026
- International Journal of Current Pharmaceutical Review and Research
- Pravar Pandya + 2 more +2
Background: Chronic plaque psoriasis is a systemic immune-mediated inflammatory dermatosis characterized by dysregulated cytokine networks and persistent cutaneous inflammation. Serum inflammatory biomarkers have emerged as potential objective indicators of disease activity, yet their precise correlation with clinical severity indices remains incompletely characterized. Methods: This cross-sectional study enrolled 120 patients with chronic plaque psoriasis and 60 age- and sexmatched healthy controls from the dermatology outpatient department of a tertiary care hospital. Patients were stratified into mild (PASI <7), moderate (PASI 7–12), and severe (PASI >12) groups. Serum biomarker levels were quantified using enzyme-linked immunosorbent assay (ELISA). Correlations between biomarker levels and PASI scores were analyzed using Spearman's rank correlation coefficient. Results: Mean serum levels of CRP (14.82 ± 6.41 mg/L vs. 2.14 ± 1.03 mg/L; p<0.001), IL-6 (28.67 ± 11.54 pg/mL vs. 5.23 ± 2.18 pg/mL; p<0.001), TNF-α (45.39 ± 18.72 pg/mL vs. 8.91 ± 3.44 pg/mL; p<0.001), and IL17A (38.56 ± 14.83 pg/mL vs. 6.47 ± 2.76 pg/mL; p<0.001) were significantly elevated in psoriasis patients compared to controls. All biomarkers demonstrated significant positive correlations with PASI scores, with IL17A exhibiting the strongest correlation (r=0.784, p<0.001). Conclusion: Serum inflammatory biomarkers are significantly elevated in chronic plaque psoriasis and correlate positively with disease severity. IL-17A demonstrated the strongest association with PASI, supporting its utility as a reliable serological indicator of disease activity and therapeutic monitoring.
Read more